Xtandi 40 MG tablet 120S
Ended Awarded
- Contract number
- SPE2DB26FKDXS
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $4,170
Award facts
- Contract value 100% obligated
- $4,169.59 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $4,169.59 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg tablets (120 count). This firm fixed-price delivery order, issued on October 20, 2025, with an ultimate completion date of October 21, 2025, was awarded without set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award falls under DMS Pharmaceutical Group's broader Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion enterprise-wide acquisition strategy designed to ensure consistent pharmaceutical supply to Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, leveraging its small business status and extensive product portfolio spanning branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables. The company's prime vendor contract under PPV-G GEN V, designated SPE2DR and valued at $499.999 billion with a completion date of December 31, 2036, authorizes the Defense Logistics Agency to issue firm fixed-price delivery orders for recurring medical supply needs across military healthcare facilities globally. DMS Pharmaceutical Group's demonstrated performance on numerous delivery orders across multiple therapeutic categories positions it as a reliable partner for supporting Department of Defense healthcare operations.
Quick answers
Who was awarded contract SPE2DB26FKDXS?
SPE2DB26FKDXS was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 20, 2025.
How much is contract SPE2DB26FKDXS worth?
The government has obligated $4,170 on SPE2DB26FKDXS.
Is contract SPE2DB26FKDXS an order under another contract?
Yes. SPE2DB26FKDXS is a delivery order under SPE2DB24D9223, an indefinite delivery contract.
Was contract SPE2DB26FKDXS competed?
The extent of competition for SPE2DB26FKDXS was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award